Spatial repellents: The current roadmap to global recommendation of spatial repellents for public health use
Spatial repellent (SR) products are envisioned to complement existing vector control methods through the continual release of volatile active ingredients (AI) providing: (i) protection against day-time and early-evening biting; (ii) protection in enclosed/semi-enclosed and peri-domestic spaces; (iii...
Saved in:
| Published in | Current research in parasitology & vector-borne diseases Vol. 3; p. 100107 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier B.V
01.01.2023
Elsevier |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Spatial repellent (SR) products are envisioned to complement existing vector control methods through the continual release of volatile active ingredients (AI) providing: (i) protection against day-time and early-evening biting; (ii) protection in enclosed/semi-enclosed and peri-domestic spaces; (iii) various formulations to fit context-specific applications; and (iv) increased coverage over traditional control methods. SR product AIs also have demonstrated effect against insecticide-resistant vectors linked to malaria and Aedes-borne virus (ABV) transmission. Over the past two decades, key stakeholders, including World Health Organization (WHO) representatives, have met to discuss the role of SRs in reducing arthropod-borne diseases based on existing evidence. A key focus has been to establish a critical development path for SRs, including scientific, regulatory and social parameters that would constitute an outline for a SR target product profile, i.e. optimum product characteristics. The principal gap is the lack of epidemiological data demonstrating SR public health impact across a range of different ecological and epidemiological settings, to inform a WHO policy recommendation. Here we describe in brief trials that are designed to fulfill evidence needs for WHO assessment and initial projections of SR cost-effectiveness against malaria and dengue.
[Display omitted]
•75 years ago the potential value of spatial repellents (SRs) for vector-borne disease control was recognized.•SR protective efficacy has been demonstrated for human Aedes-borne virus infections and efficacy results for human malaria infections are promising.•Initial projections indicate that SRs have public health and economic benefits.•Limited data exists on (i) human behavior and SR use and (ii) when and where SRs are needed.•WHO requirements on SR epidemiological efficacy are partially satisfied. |
|---|---|
| AbstractList | Spatial repellent (SR) products are envisioned to complement existing vector control methods through the continual release of volatile active ingredients (AI) providing: (i) protection against day-time and early-evening biting; (ii) protection in enclosed/semi-enclosed and peri-domestic spaces; (iii) various formulations to fit context-specific applications; and (iv) increased coverage over traditional control methods. SR product AIs also have demonstrated effect against insecticide-resistant vectors linked to malaria and
Aedes-
borne virus (ABV) transmission. Over the past two decades, key stakeholders, including World Health Organization (WHO) representatives, have met to discuss the role of SRs in reducing arthropod-borne diseases based on existing evidence. A key focus has been to establish a critical development path for SRs, including scientific, regulatory and social parameters that would constitute an outline for a SR target product profile, i.e. optimum product characteristics. The principal gap is the lack of epidemiological data demonstrating SR public health impact across a range of different ecological and epidemiological settings, to inform a WHO policy recommendation. Here we describe in brief trials that are designed to fulfill evidence needs for WHO assessment and initial projections of SR cost-effectiveness against malaria and dengue.
Image 1
•
75 years ago the potential value of spatial repellents (SRs) for vector-borne disease control was recognized.
•
SR protective efficacy has been demonstrated for human
Aedes
-borne virus infections and efficacy results for human malaria infections are promising.
•
Initial projections indicate that SRs have public health and economic benefits.
•
Limited data exists on (i) human behavior and SR use and (ii) when and where SRs are needed.
•
WHO requirements on SR epidemiological efficacy are partially satisfied. Spatial repellent (SR) products are envisioned to complement existing vector control methods through the continual release of volatile active ingredients (AI) providing: (i) protection against day-time and early-evening biting; (ii) protection in enclosed/semi-enclosed and peri-domestic spaces; (iii) various formulations to fit context-specific applications; and (iv) increased coverage over traditional control methods. SR product AIs also have demonstrated effect against insecticide-resistant vectors linked to malaria and Aedes-borne virus (ABV) transmission. Over the past two decades, key stakeholders, including World Health Organization (WHO) representatives, have met to discuss the role of SRs in reducing arthropod-borne diseases based on existing evidence. A key focus has been to establish a critical development path for SRs, including scientific, regulatory and social parameters that would constitute an outline for a SR target product profile, i.e. optimum product characteristics. The principal gap is the lack of epidemiological data demonstrating SR public health impact across a range of different ecological and epidemiological settings, to inform a WHO policy recommendation. Here we describe in brief trials that are designed to fulfill evidence needs for WHO assessment and initial projections of SR cost-effectiveness against malaria and dengue.Spatial repellent (SR) products are envisioned to complement existing vector control methods through the continual release of volatile active ingredients (AI) providing: (i) protection against day-time and early-evening biting; (ii) protection in enclosed/semi-enclosed and peri-domestic spaces; (iii) various formulations to fit context-specific applications; and (iv) increased coverage over traditional control methods. SR product AIs also have demonstrated effect against insecticide-resistant vectors linked to malaria and Aedes-borne virus (ABV) transmission. Over the past two decades, key stakeholders, including World Health Organization (WHO) representatives, have met to discuss the role of SRs in reducing arthropod-borne diseases based on existing evidence. A key focus has been to establish a critical development path for SRs, including scientific, regulatory and social parameters that would constitute an outline for a SR target product profile, i.e. optimum product characteristics. The principal gap is the lack of epidemiological data demonstrating SR public health impact across a range of different ecological and epidemiological settings, to inform a WHO policy recommendation. Here we describe in brief trials that are designed to fulfill evidence needs for WHO assessment and initial projections of SR cost-effectiveness against malaria and dengue. Spatial repellent (SR) products are envisioned to complement existing vector control methods through the continual release of volatile active ingredients (AI) providing: (i) protection against day-time and early-evening biting; (ii) protection in enclosed/semi-enclosed and peri-domestic spaces; (iii) various formulations to fit context-specific applications; and (iv) increased coverage over traditional control methods. SR product AIs also have demonstrated effect against insecticide-resistant vectors linked to malaria and borne virus (ABV) transmission. Over the past two decades, key stakeholders, including World Health Organization (WHO) representatives, have met to discuss the role of SRs in reducing arthropod-borne diseases based on existing evidence. A key focus has been to establish a critical development path for SRs, including scientific, regulatory and social parameters that would constitute an outline for a SR target product profile, i.e. optimum product characteristics. The principal gap is the lack of epidemiological data demonstrating SR public health impact across a range of different ecological and epidemiological settings, to inform a WHO policy recommendation. Here we describe in brief trials that are designed to fulfill evidence needs for WHO assessment and initial projections of SR cost-effectiveness against malaria and dengue. Spatial repellent (SR) products are envisioned to complement existing vector control methods through the continual release of volatile active ingredients (AI) providing: (i) protection against day-time and early-evening biting; (ii) protection in enclosed/semi-enclosed and peri-domestic spaces; (iii) various formulations to fit context-specific applications; and (iv) increased coverage over traditional control methods. SR product AIs also have demonstrated effect against insecticide-resistant vectors linked to malaria and Aedes-borne virus (ABV) transmission. Over the past two decades, key stakeholders, including World Health Organization (WHO) representatives, have met to discuss the role of SRs in reducing arthropod-borne diseases based on existing evidence. A key focus has been to establish a critical development path for SRs, including scientific, regulatory and social parameters that would constitute an outline for a SR target product profile, i.e. optimum product characteristics. The principal gap is the lack of epidemiological data demonstrating SR public health impact across a range of different ecological and epidemiological settings, to inform a WHO policy recommendation. Here we describe in brief trials that are designed to fulfill evidence needs for WHO assessment and initial projections of SR cost-effectiveness against malaria and dengue. Spatial repellent (SR) products are envisioned to complement existing vector control methods through the continual release of volatile active ingredients (AI) providing: (i) protection against day-time and early-evening biting; (ii) protection in enclosed/semi-enclosed and peri-domestic spaces; (iii) various formulations to fit context-specific applications; and (iv) increased coverage over traditional control methods. SR product AIs also have demonstrated effect against insecticide-resistant vectors linked to malaria and Aedes-borne virus (ABV) transmission. Over the past two decades, key stakeholders, including World Health Organization (WHO) representatives, have met to discuss the role of SRs in reducing arthropod-borne diseases based on existing evidence. A key focus has been to establish a critical development path for SRs, including scientific, regulatory and social parameters that would constitute an outline for a SR target product profile, i.e. optimum product characteristics. The principal gap is the lack of epidemiological data demonstrating SR public health impact across a range of different ecological and epidemiological settings, to inform a WHO policy recommendation. Here we describe in brief trials that are designed to fulfill evidence needs for WHO assessment and initial projections of SR cost-effectiveness against malaria and dengue. [Display omitted] •75 years ago the potential value of spatial repellents (SRs) for vector-borne disease control was recognized.•SR protective efficacy has been demonstrated for human Aedes-borne virus infections and efficacy results for human malaria infections are promising.•Initial projections indicate that SRs have public health and economic benefits.•Limited data exists on (i) human behavior and SR use and (ii) when and where SRs are needed.•WHO requirements on SR epidemiological efficacy are partially satisfied. |
| ArticleNumber | 100107 |
| Author | Moore, Sean M. Reiner, Robert C. Harvey, Steven A. Achee, Nicole L. Morrison, Amy C. Grieco, John P. Tissera, Hasitha A. Ochomo, Eric O. Van Hulle, Suzanne Sagara, Issaka Perkins, T. Alex Monroe, April Scott, Thomas W. Liu, Fang Gimnig, John E. |
| Author_xml | – sequence: 1 givenname: Nicole L. surname: Achee fullname: Achee, Nicole L. email: nachee@nd.edu organization: Department of Biological Sciences, Eck Institute for Global Health, University of Notre Dame, Notre Dame, IN, USA – sequence: 2 givenname: T. Alex surname: Perkins fullname: Perkins, T. Alex organization: Department of Biological Sciences, Eck Institute for Global Health, University of Notre Dame, Notre Dame, IN, USA – sequence: 3 givenname: Sean M. surname: Moore fullname: Moore, Sean M. organization: Department of Biological Sciences, Eck Institute for Global Health, University of Notre Dame, Notre Dame, IN, USA – sequence: 4 givenname: Fang surname: Liu fullname: Liu, Fang organization: Department of Applied and Computational Mathematics and Statistics, University of Notre Dame, Notre Dame, IN, USA – sequence: 5 givenname: Issaka surname: Sagara fullname: Sagara, Issaka organization: Malaria Research and Training Center (MRTC), Faculty of Medicine, Dentistry and Pharmacy at the University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali – sequence: 6 givenname: Suzanne surname: Van Hulle fullname: Van Hulle, Suzanne organization: Catholic Relief Services, Baltimore, MD, USA – sequence: 7 givenname: Eric O. surname: Ochomo fullname: Ochomo, Eric O. organization: Kenya Medical Research Institute, Centre for Global Health Research, Kisumu, Kenya – sequence: 8 givenname: John E. surname: Gimnig fullname: Gimnig, John E. organization: Centers for Disease Control and Prevention, Division of Parasitic Diseases and Malaria, Atlanta, GA, USA – sequence: 9 givenname: Hasitha A. surname: Tissera fullname: Tissera, Hasitha A. organization: Epidemiology Unit, Ministry of Health, Sri Lanka – sequence: 10 givenname: Steven A. surname: Harvey fullname: Harvey, Steven A. organization: Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA – sequence: 11 givenname: April surname: Monroe fullname: Monroe, April organization: Johns Hopkins Center for Communication Programs, Baltimore, MD, USA – sequence: 12 givenname: Amy C. surname: Morrison fullname: Morrison, Amy C. organization: Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California, Davis, CA, USA – sequence: 13 givenname: Thomas W. surname: Scott fullname: Scott, Thomas W. organization: Department of Entomology and Nematology, University of California, Davis, CA, USA – sequence: 14 givenname: Robert C. surname: Reiner fullname: Reiner, Robert C. organization: Department of Health Metrics Sciences, University of Washington, Seattle, WA, USA – sequence: 15 givenname: John P. surname: Grieco fullname: Grieco, John P. organization: Department of Biological Sciences, Eck Institute for Global Health, University of Notre Dame, Notre Dame, IN, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36590345$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFks1u3CAUha0qVZOmeYOqYtnNTAEbMFlUqqL-RIrURVOpO4ThMsMIGxfskfL2JeNplLRSuzKGcz-495yX1ckQB6iq1wSvCSb83W5t0rjv7JpiSssWJlg8q84o52JFSPPj5NH6tLrIeYcxpozUtWheVKc1ZxLXDTurwrdRT14HlGCEEGCY8iW63QIyc0rlD6Woba9HNEW0CbE7KE3sexhsKYwDig7lvxjIxYTGuQveoC3oMG3RnOFV9dzpkOHi-D2vvn_6eHv1ZXXz9fP11YeblWFUTitLW24pNrKFTrQWtKPYMSo4d512XHZasIaJ2knDuNSCWEOMtA3B3FpW2_q8ul64NuqdGpPvdbpTUXt12Ihpo3SavAmgeF3ItRMtSNlQqVshwFnXNEIKazEprPcLq3TTgzWlu6TDE-jTk8Fv1SbulWyLKS0rgLdHQIo_Z8iT6n02ZU56gDhnVfoqjractkX65vFdD5f8tqsImkVgUsw5gXuQEKzug6F2agmGug-GWoJRyi7_KDN-OrhXXuzD_4qPA4Di2N5DUtl4GAxYX5IwlZH6fwN-AfUw2C8 |
| CitedBy_id | crossref_primary_10_1186_s12936_024_05043_5 crossref_primary_10_3201_eid2912_230637 crossref_primary_10_1371_journal_pone_0300368 crossref_primary_10_1371_journal_pone_0299722 crossref_primary_10_1186_s13063_024_08378_1 crossref_primary_10_1186_s12936_024_04841_1 crossref_primary_10_1371_journal_pone_0298919 crossref_primary_10_3389_finsc_2024_1320138 crossref_primary_10_1093_jisesa_ieae103 crossref_primary_10_1186_s12936_024_05188_3 crossref_primary_10_1111_jen_13330 crossref_primary_10_1371_journal_pntd_0012060 crossref_primary_10_1038_s41598_024_61116_0 crossref_primary_10_3390_insects16030265 crossref_primary_10_1186_s12942_024_00381_8 crossref_primary_10_1038_s41598_024_67470_3 crossref_primary_10_1186_s12936_024_04982_3 crossref_primary_10_1155_2024_5843481 |
| Cites_doi | 10.1186/s12936-016-1461-9 10.1186/1475-2875-13-208 10.1371/journal.pone.0149738 10.1371/journal.pmed.1002181 10.1371/journal.pone.0110433 10.1038/nature12060 10.1016/S1473-3099(16)30518-7 10.1038/nature15535 10.1371/journal.pone.0187680 10.3390/ijerph14020124 10.1371/journal.pntd.0003655 10.1016/j.vaccine.2016.11.042 10.1186/s12936-015-0692-5 10.1016/S1473-3099(10)70096-7 10.1016/S0140-6736(16)31012-1 10.1073/pnas.2118283119 10.1186/1475-2875-9-240 10.1186/s13063-022-06197-w 10.1371/journal.pntd.0001760 10.1186/s12936-016-1187-8 10.1016/S1473-3099(16)00146-8 10.1016/S1473-3099(16)00026-8 10.1371/journal.ppat.1006965 10.4269/ajtmh.13-0735 10.1186/s13071-018-2919-0 10.1186/s13063-022-06196-x 10.1371/journal.pmed.0050068 10.1186/1475-2875-11-164 10.4269/ajtmh.19-0554 10.1186/1475-2875-10-337 |
| ContentType | Journal Article |
| Copyright | 2022 The Authors 2022 The Authors. 2022 The Authors 2022 |
| Copyright_xml | – notice: 2022 The Authors – notice: 2022 The Authors. – notice: 2022 The Authors 2022 |
| DBID | 6I. AAFTH AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.1016/j.crpvbd.2022.100107 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2667-114X |
| ExternalDocumentID | oai_doaj_org_article_63f523f78e99429a877efdf44797dd01 PMC9801085 36590345 10_1016_j_crpvbd_2022_100107 S2667114X22000334 |
| Genre | Journal Article |
| GroupedDBID | 6I. AAEDW AAFTH AAXUO AEXQZ ALMA_UNASSIGNED_HOLDINGS AMRAJ EBS FDB GROUPED_DOAJ M~E OK1 ROL RPM 0R~ AAHBH AALRI AAYWO AAYXX ACVFH ADCNI ADVLN AEUPX AFJKZ AFPUW AIGII AITUG AKBMS AKRWK AKYEP APXCP CITATION NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c529t-d286d20c98eb78deaf20f52766fbaf69ba754573f9c569a71dc1c9d4106dd53d3 |
| IEDL.DBID | DOA |
| ISSN | 2667-114X |
| IngestDate | Wed Aug 27 01:31:28 EDT 2025 Thu Aug 21 18:40:15 EDT 2025 Fri Jul 11 10:22:22 EDT 2025 Thu Jan 02 22:54:02 EST 2025 Thu Apr 24 22:51:40 EDT 2025 Tue Jul 01 00:49:39 EDT 2025 Fri Feb 23 02:37:39 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Spatial repellents Malaria Social science Dengue Clinical trials Cost-effectiveness WHO |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. 2022 The Authors. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c529t-d286d20c98eb78deaf20f52766fbaf69ba754573f9c569a71dc1c9d4106dd53d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://doaj.org/article/63f523f78e99429a877efdf44797dd01 |
| PMID | 36590345 |
| PQID | 2760168628 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_63f523f78e99429a877efdf44797dd01 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9801085 proquest_miscellaneous_2760168628 pubmed_primary_36590345 crossref_primary_10_1016_j_crpvbd_2022_100107 crossref_citationtrail_10_1016_j_crpvbd_2022_100107 elsevier_sciencedirect_doi_10_1016_j_crpvbd_2022_100107 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-01-01 |
| PublicationDateYYYYMMDD | 2023-01-01 |
| PublicationDate_xml | – month: 01 year: 2023 text: 2023-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Current research in parasitology & vector-borne diseases |
| PublicationTitleAlternate | Curr Res Parasitol Vector Borne Dis |
| PublicationYear | 2023 |
| Publisher | Elsevier B.V Elsevier |
| Publisher_xml | – name: Elsevier B.V – name: Elsevier |
| References | ten Bosch, Clapham, Lambrechts, Duoung, Buchy, Althouse (bib30) 2018; 14 White, Conteh, Cibulskis, Ghani (bib35) 2011; 10 Yukich, J., Tediosi, F., Lengeler, C., 2007. Operations, costs and cost-effectiveness of five insecticide-treated net programs (Eritrea, Malawi, Tanzania, Togo, Senegal) and two indoor residual spraying programs (Kwa-Zulu-Natal, Mozambique). USAID Report, 12 July 2007 Swiss Tropical Institute, Basel, Switzerland, 130 pp. Shepard, Undurraga, Halasa, Stanaway (bib24) 2016; 16 Wang, Naghavi, Allen, Barber, Bhutta, Carter (bib34) 2016; 388 (Accessed 16 November 2022). Korenromp, Mahiané, Hamilton, Pretorius, Cibulskis, Lauer (bib14) 2016; 15 ten Bosch, Wagman, Castro-Llanos, Achee, Grieco, Perkins (bib31) 2019; 16 Morrison, Reiner, Elson, Astete, Guevara, Del Aguila (bib16) 2022; 119 Syafruddin, Asih, Rozi, Permana, Hidayati, Syahrani (bib28) 2020; 103 WHO, 2020. Overview of intervention classes and prototype/products under Vector Control Advisory Group (VCAG) review for assessment of public health value. World Health Organization, Geneva. Sinka, Golding, Massey, Wiebe, Huang, Hay, Moyes (bib25) 2016; 15 (bib38) 2017 OʼMeara, Mangeni, Steketee, Greenwood (bib22) 2010; 10 WHO, 2022. Terms of reference of the Vector Control Advisory Group (VCAG). World Health Organization, Geneva Assessed (Accessed 1 December 2022). Achee, Bangs, Farlow, Killeen, Lindsay, Logan (bib1) 2012; 11 Ogoma, Ngonyani, Simfukwe, Mseka, Moore, Maia, Moore, Lorenz (bib20) 2014; 9 Van Hulle, Sagara, Mbodji, Nana, Coulibaly, Dicko (bib32) 2022; 23 Wagman, Grieco, Bautista, Polanco, Briceño, King, Achee (bib33) 2015; 14 Norris, Coats (bib18) 2017; 14 (bib42) 2017 Ritchie, Devine, Vazquez-Prokopec, Lenhart, Manrique-Saide, Scott (bib23) 2021 Ochomo, Gimnig, Bhattarai, Samuels, Kariuki, Okello (bib19) 2022; 23 Flasche, Jit, Rodriguez-Barraquer, Coudeville, Recker, Koelle (bib9) 2016; 13 (bib37) 2013 AEGIS (bib4) 2022 Bhatt, Gething, Brady, Messina, Farlow, Moyes (bib6) 2013; 496 Brady, Gething, Bhatt, Messina, Brownstein, Hoen (bib7) 2012; 6 Kiware, Chitnis, Tatarsky, Wu, Castellanos, Gosling (bib13) 2017; 12 (bib36) 2013 Achee, Gould, Perkins, Reiner, Morrison, Ritchie (bib2) 2015; 9 Wilder-Smith, Gubler, Weaver, Monath, Heymann, Scott (bib43) 2017; 17 Galactionova, Tediosi, Camponovo, Smith, Gething, Penny (bib10) 2017; 35 Morrison, Zielinski-Gutierrez, Scott, Rosenberg (bib15) 2008; 5 Horstmann, Sonneck (bib12) 2016; 11 (bib40) 2021 Hill, Zhou, Wang, Guo, Carneiro, Moore (bib11) 2014; 13 Bhatt, Weiss, Cameron, Bisanzio, Mappin, Dalrympe (bib45) 2015; 526 D’Acremont, Lengeler, Genton (bib8) 2010; 9 Nolden, Brockmann, Ebbinghaus-Kintscher, Brueggen, Horstmann, Paine, Nauen (bib17) 2021; 1 OʼMeara, Mangeni, Steketee, Greenwood (bib21) 2010; 10 Syafruddin, Bangs, Sidik, Elyazar, Asih, Chan (bib27) 2014; 91 Stanaway, Shepard, Undurraga, Halasa, Coffeng, Brady (bib26) 2016; 16 ten Bosch, Castro-Llanos, Manda, Morrison, Grieco, Achee, Perkins (bib29) 2018; 11 Morrison (10.1016/j.crpvbd.2022.100107_bib15) 2008; 5 Horstmann (10.1016/j.crpvbd.2022.100107_bib12) 2016; 11 White (10.1016/j.crpvbd.2022.100107_bib35) 2011; 10 Morrison (10.1016/j.crpvbd.2022.100107_bib16) 2022; 119 Wagman (10.1016/j.crpvbd.2022.100107_bib33) 2015; 14 Wilder-Smith (10.1016/j.crpvbd.2022.100107_bib43) 2017; 17 Nolden (10.1016/j.crpvbd.2022.100107_bib17) 2021; 1 ten Bosch (10.1016/j.crpvbd.2022.100107_bib31) 2019; 16 ten Bosch (10.1016/j.crpvbd.2022.100107_bib29) 2018; 11 Galactionova (10.1016/j.crpvbd.2022.100107_bib10) 2017; 35 OʼMeara (10.1016/j.crpvbd.2022.100107_bib22) 2010; 10 Korenromp (10.1016/j.crpvbd.2022.100107_bib14) 2016; 15 Shepard (10.1016/j.crpvbd.2022.100107_bib24) 2016; 16 Van Hulle (10.1016/j.crpvbd.2022.100107_bib32) 2022; 23 Achee (10.1016/j.crpvbd.2022.100107_bib1) 2012; 11 Ritchie (10.1016/j.crpvbd.2022.100107_bib23) 2021 Syafruddin (10.1016/j.crpvbd.2022.100107_bib28) 2020; 103 (10.1016/j.crpvbd.2022.100107_bib36) 2013 Hill (10.1016/j.crpvbd.2022.100107_bib11) 2014; 13 10.1016/j.crpvbd.2022.100107_bib44 OʼMeara (10.1016/j.crpvbd.2022.100107_bib21) 2010; 10 10.1016/j.crpvbd.2022.100107_bib41 Flasche (10.1016/j.crpvbd.2022.100107_bib9) 2016; 13 Syafruddin (10.1016/j.crpvbd.2022.100107_bib27) 2014; 91 ten Bosch (10.1016/j.crpvbd.2022.100107_bib30) 2018; 14 Ogoma (10.1016/j.crpvbd.2022.100107_bib20) 2014; 9 Ochomo (10.1016/j.crpvbd.2022.100107_bib19) 2022; 23 (10.1016/j.crpvbd.2022.100107_bib40) 2021 (10.1016/j.crpvbd.2022.100107_bib38) 2017 Achee (10.1016/j.crpvbd.2022.100107_bib2) 2015; 9 Stanaway (10.1016/j.crpvbd.2022.100107_bib26) 2016; 16 Bhatt (10.1016/j.crpvbd.2022.100107_bib45) 2015; 526 Brady (10.1016/j.crpvbd.2022.100107_bib7) 2012; 6 Wang (10.1016/j.crpvbd.2022.100107_bib34) 2016; 388 (10.1016/j.crpvbd.2022.100107_bib37) 2013 (10.1016/j.crpvbd.2022.100107_bib42) 2017 Bhatt (10.1016/j.crpvbd.2022.100107_bib6) 2013; 496 D’Acremont (10.1016/j.crpvbd.2022.100107_bib8) 2010; 9 Kiware (10.1016/j.crpvbd.2022.100107_bib13) 2017; 12 Norris (10.1016/j.crpvbd.2022.100107_bib18) 2017; 14 Sinka (10.1016/j.crpvbd.2022.100107_bib25) 2016; 15 AEGIS (10.1016/j.crpvbd.2022.100107_bib4) 2022 10.1016/j.crpvbd.2022.100107_bib39 |
| References_xml | – volume: 9 year: 2015 ident: bib2 article-title: A critical assessment of vector control for dengue prevention publication-title: PLoS Negl. Trop. Dis. – volume: 15 start-page: 417 year: 2016 ident: bib14 article-title: Malaria intervention scale-up in Africa: Effectiveness predictions for health programme planning tools, based on dynamic transmission modelling publication-title: Malar. J. – volume: 14 year: 2018 ident: bib30 article-title: Contributions from the silent majority dominate dengue virus transmission publication-title: PLoS Pathog. – volume: 16 start-page: 935 year: 2016 end-page: 941 ident: bib24 article-title: The global economic burden of dengue: A systematic analysis publication-title: Lancet Infect. Dis. – volume: 10 start-page: 545 year: 2010 end-page: 555 ident: bib22 article-title: Changes in the burden of malaria in sub-Saharan Africa publication-title: Lancet Infect. Dis. – volume: 1 year: 2021 ident: bib17 article-title: Towards understanding transfluthrin efficacy in a pyrethroid-resistant strain of the malaria vector publication-title: Curr. Res. Parasitol. Vector Borne Dis. – year: 2017 ident: bib42 article-title: Global Vector Control Response 2017–2030 – volume: 6 year: 2012 ident: bib7 article-title: Refining the global spatial limits of dengue virus transmission by evidence-based consensus publication-title: PLoS Negl. Trop. Dis. – volume: 11 start-page: 365 year: 2018 ident: bib29 article-title: Model-based analysis of experimental data from interconnected, row-configured huts elucidates multifaceted effects of a volatile chemical on publication-title: Parasites Vectors – reference: Yukich, J., Tediosi, F., Lengeler, C., 2007. Operations, costs and cost-effectiveness of five insecticide-treated net programs (Eritrea, Malawi, Tanzania, Togo, Senegal) and two indoor residual spraying programs (Kwa-Zulu-Natal, Mozambique). USAID Report, 12 July 2007 Swiss Tropical Institute, Basel, Switzerland, 130 pp. – reference: WHO, 2020. Overview of intervention classes and prototype/products under Vector Control Advisory Group (VCAG) review for assessment of public health value. World Health Organization, Geneva. – volume: 23 start-page: 259 year: 2022 ident: bib32 article-title: Evaluation of the protective efficacy of a spatial repellent to reduce malaria incidence in children in Mali compared to placebo: Study protocol for a cluster-randomized double-blinded control trial (the AEGIS program) publication-title: Trials – volume: 9 start-page: 240 year: 2010 ident: bib8 article-title: Reduction in the proportion of fevers associated with publication-title: Malar. J. – volume: 388 start-page: 1459 year: 2016 end-page: 1544 ident: bib34 article-title: Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: A systematic analysis for the Global Burden of Disease Study 2015 publication-title: Lancet – volume: 526 start-page: 207 year: 2015 end-page: 211 ident: bib45 article-title: The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015 publication-title: Nature – volume: 119 year: 2022 ident: bib16 article-title: Efficacy of a spatial repellent for control of publication-title: Proc. Natl. Acad. Sci. USA – volume: 11 start-page: 164 year: 2012 ident: bib1 article-title: Spatial repellents: from discovery and development to evidence-based validation publication-title: Malar. J. – volume: 35 start-page: 53 year: 2017 end-page: 60 ident: bib10 article-title: Country specific predictions of the cost-effectiveness of malaria vaccine RTS, S/AS01 in endemic Africa publication-title: Vaccine – volume: 14 start-page: 184 year: 2015 ident: bib33 article-title: The field evaluation of a push-pull system to control malaria vectors in Northern Belize, Central America publication-title: Malar. J. – reference: (Accessed 1 December 2022). – volume: 13 year: 2016 ident: bib9 article-title: The long-term safety, public health impact, and cost-effectiveness of routine vaccination with a recombinant, live-attenuated dengue vaccine (Dengvaxia): A model comparison study publication-title: PLoS Med. – year: 2017 ident: bib38 article-title: Seventh Meeting of the Vector Control Advisory Group, Geneva, Switzerland, 24–26 October 2017 – volume: 496 start-page: 504 year: 2013 end-page: 507 ident: bib6 article-title: The global distribution and burden of dengue publication-title: Nature – volume: 5 start-page: e68 year: 2008 ident: bib15 article-title: Defining the challenges and proposing new solutions for publication-title: PLoS Med. – volume: 103 start-page: 344 year: 2020 ident: bib28 article-title: Efficacy of a spatial repellent for control of malaria in Indonesia: A cluster-randomized controlled trial publication-title: Am. J. Trop. Med. Hyg. – volume: 10 start-page: 337 year: 2011 ident: bib35 article-title: Costs and cost-effectiveness of malaria control interventions - a systematic review publication-title: Malar. J. – year: 2013 ident: bib37 article-title: Guidelines for efficacy testing of spatial repellents – year: 2013 ident: bib36 article-title: How to design vector control efficacy trials: Guidance on phase III vector control field trial design provided by the Vector Control Advisory Group – year: 2021 ident: bib40 article-title: World Malaria Report 2021 – volume: 12 year: 2017 ident: bib13 article-title: Attacking the mosquito on multiple fronts: insights from the vector control optimization model (VCOM) for malaria elimination publication-title: PLoS One – start-page: 59 year: 2021 end-page: 89 ident: bib23 article-title: Insecticide-based approaches for dengue vector control publication-title: Innovative Strategies for Vector Control – year: 2022 ident: bib4 article-title: Spatial repellents for Aedes-borne virus control in Sri Lanka (AEGIS ABV). ClinicalTrials.gov identifier: NCT05452447 – volume: 11 year: 2016 ident: bib12 article-title: Contact bioassays with phenoxybenzyl and tetrafluorobenzyl pyrethroids against target-site and metabolic resistant mosquitoes publication-title: PLoS One – reference: . (Accessed 16 November 2022). – volume: 16 start-page: 712 year: 2016 end-page: 723 ident: bib26 article-title: The global burden of dengue: An analysis from the Global Burden of Disease Study 2013 publication-title: Lancet Infect. Dis. – volume: 14 start-page: 124 year: 2017 ident: bib18 article-title: Current and future repellent technologies: the potential of spatial repellents and their place in mosquito-borne disease control publication-title: Int. J. Environ. Res. Publ. Health – volume: 9 year: 2014 ident: bib20 article-title: The mode of action of spatial repellents and their impact on vectorial capacity of publication-title: PLoS One – volume: 16 year: 2019 ident: bib31 article-title: Community-level impacts of spatial repellents for control of diseases vectored by publication-title: PLoS Comput. Biol. – reference: WHO, 2022. Terms of reference of the Vector Control Advisory Group (VCAG). World Health Organization, Geneva Assessed – volume: 23 start-page: 260 year: 2022 ident: bib19 article-title: Evaluation of the protective efficacy of a spatial repellent to reduce malaria incidence in children in western Kenya compared to placebo: study protocol for a cluster-randomized double-blinded control trial (the AEGIS program) publication-title: Trials – volume: 15 start-page: 142 year: 2016 ident: bib25 article-title: Modelling the relative abundance of the primary African vectors of malaria before and after the implementation of indoor, insecticide-based vector control publication-title: Malar. J. – volume: 10 start-page: 545 year: 2010 end-page: 555 ident: bib21 article-title: Changes in the burden of malaria in sub-Saharan Africa publication-title: Lancet Infect. Dis. – volume: 91 start-page: 1079 year: 2014 ident: bib27 article-title: Impact of a spatial repellent on malaria incidence in two villages in Sumba, Indonesia publication-title: Am. J. Trop. Med. Hyg. – volume: 13 start-page: 208 year: 2014 ident: bib11 article-title: A household randomized, controlled trial of the efficacy of 0.03% transfluthrin coils alone and in combination with long-lasting insecticidal nets on the incidence of publication-title: Malar. J. – volume: 17 start-page: e101 year: 2017 end-page: e106 ident: bib43 article-title: Epidemic arboviral diseases: Priorities for research and public health publication-title: Lancet Infect. Dis. – ident: 10.1016/j.crpvbd.2022.100107_bib41 – volume: 15 start-page: 417 year: 2016 ident: 10.1016/j.crpvbd.2022.100107_bib14 article-title: Malaria intervention scale-up in Africa: Effectiveness predictions for health programme planning tools, based on dynamic transmission modelling publication-title: Malar. J. doi: 10.1186/s12936-016-1461-9 – volume: 13 start-page: 208 year: 2014 ident: 10.1016/j.crpvbd.2022.100107_bib11 article-title: A household randomized, controlled trial of the efficacy of 0.03% transfluthrin coils alone and in combination with long-lasting insecticidal nets on the incidence of Plasmodium falciparum and Plasmodium vivax malaria in Western Yunnan Province, China publication-title: Malar. J. doi: 10.1186/1475-2875-13-208 – volume: 11 year: 2016 ident: 10.1016/j.crpvbd.2022.100107_bib12 article-title: Contact bioassays with phenoxybenzyl and tetrafluorobenzyl pyrethroids against target-site and metabolic resistant mosquitoes publication-title: PLoS One doi: 10.1371/journal.pone.0149738 – ident: 10.1016/j.crpvbd.2022.100107_bib39 – volume: 13 year: 2016 ident: 10.1016/j.crpvbd.2022.100107_bib9 article-title: The long-term safety, public health impact, and cost-effectiveness of routine vaccination with a recombinant, live-attenuated dengue vaccine (Dengvaxia): A model comparison study publication-title: PLoS Med. doi: 10.1371/journal.pmed.1002181 – volume: 9 year: 2014 ident: 10.1016/j.crpvbd.2022.100107_bib20 article-title: The mode of action of spatial repellents and their impact on vectorial capacity of Anopheles gambiae sensu stricto publication-title: PLoS One doi: 10.1371/journal.pone.0110433 – volume: 496 start-page: 504 year: 2013 ident: 10.1016/j.crpvbd.2022.100107_bib6 article-title: The global distribution and burden of dengue publication-title: Nature doi: 10.1038/nature12060 – volume: 17 start-page: e101 year: 2017 ident: 10.1016/j.crpvbd.2022.100107_bib43 article-title: Epidemic arboviral diseases: Priorities for research and public health publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(16)30518-7 – volume: 526 start-page: 207 year: 2015 ident: 10.1016/j.crpvbd.2022.100107_bib45 article-title: The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015 publication-title: Nature doi: 10.1038/nature15535 – volume: 12 year: 2017 ident: 10.1016/j.crpvbd.2022.100107_bib13 article-title: Attacking the mosquito on multiple fronts: insights from the vector control optimization model (VCOM) for malaria elimination publication-title: PLoS One doi: 10.1371/journal.pone.0187680 – volume: 14 start-page: 124 year: 2017 ident: 10.1016/j.crpvbd.2022.100107_bib18 article-title: Current and future repellent technologies: the potential of spatial repellents and their place in mosquito-borne disease control publication-title: Int. J. Environ. Res. Publ. Health doi: 10.3390/ijerph14020124 – volume: 9 year: 2015 ident: 10.1016/j.crpvbd.2022.100107_bib2 article-title: A critical assessment of vector control for dengue prevention publication-title: PLoS Negl. Trop. Dis. doi: 10.1371/journal.pntd.0003655 – volume: 35 start-page: 53 year: 2017 ident: 10.1016/j.crpvbd.2022.100107_bib10 article-title: Country specific predictions of the cost-effectiveness of malaria vaccine RTS, S/AS01 in endemic Africa publication-title: Vaccine doi: 10.1016/j.vaccine.2016.11.042 – volume: 14 start-page: 184 year: 2015 ident: 10.1016/j.crpvbd.2022.100107_bib33 article-title: The field evaluation of a push-pull system to control malaria vectors in Northern Belize, Central America publication-title: Malar. J. doi: 10.1186/s12936-015-0692-5 – volume: 10 start-page: 545 year: 2010 ident: 10.1016/j.crpvbd.2022.100107_bib22 article-title: Changes in the burden of malaria in sub-Saharan Africa publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(10)70096-7 – volume: 1 year: 2021 ident: 10.1016/j.crpvbd.2022.100107_bib17 article-title: Towards understanding transfluthrin efficacy in a pyrethroid-resistant strain of the malaria vector Anopheles funestus with special reference to cytochrome P450-mediated detoxification publication-title: Curr. Res. Parasitol. Vector Borne Dis. – volume: 388 start-page: 1459 year: 2016 ident: 10.1016/j.crpvbd.2022.100107_bib34 article-title: Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: A systematic analysis for the Global Burden of Disease Study 2015 publication-title: Lancet doi: 10.1016/S0140-6736(16)31012-1 – year: 2017 ident: 10.1016/j.crpvbd.2022.100107_bib42 – start-page: 59 year: 2021 ident: 10.1016/j.crpvbd.2022.100107_bib23 article-title: Insecticide-based approaches for dengue vector control – year: 2017 ident: 10.1016/j.crpvbd.2022.100107_bib38 – year: 2013 ident: 10.1016/j.crpvbd.2022.100107_bib36 – year: 2021 ident: 10.1016/j.crpvbd.2022.100107_bib40 – volume: 119 year: 2022 ident: 10.1016/j.crpvbd.2022.100107_bib16 article-title: Efficacy of a spatial repellent for control of Aedes-borne virus transmission: A cluster-randomized trial in Iquitos, Peru publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.2118283119 – ident: 10.1016/j.crpvbd.2022.100107_bib44 – volume: 9 start-page: 240 year: 2010 ident: 10.1016/j.crpvbd.2022.100107_bib8 article-title: Reduction in the proportion of fevers associated with Plasmodium falciparum parasitaemia in Africa: A systematic review publication-title: Malar. J. doi: 10.1186/1475-2875-9-240 – volume: 23 start-page: 259 year: 2022 ident: 10.1016/j.crpvbd.2022.100107_bib32 article-title: Evaluation of the protective efficacy of a spatial repellent to reduce malaria incidence in children in Mali compared to placebo: Study protocol for a cluster-randomized double-blinded control trial (the AEGIS program) publication-title: Trials doi: 10.1186/s13063-022-06197-w – volume: 6 year: 2012 ident: 10.1016/j.crpvbd.2022.100107_bib7 article-title: Refining the global spatial limits of dengue virus transmission by evidence-based consensus publication-title: PLoS Negl. Trop. Dis. doi: 10.1371/journal.pntd.0001760 – year: 2013 ident: 10.1016/j.crpvbd.2022.100107_bib37 – volume: 15 start-page: 142 year: 2016 ident: 10.1016/j.crpvbd.2022.100107_bib25 article-title: Modelling the relative abundance of the primary African vectors of malaria before and after the implementation of indoor, insecticide-based vector control publication-title: Malar. J. doi: 10.1186/s12936-016-1187-8 – volume: 16 start-page: 935 year: 2016 ident: 10.1016/j.crpvbd.2022.100107_bib24 article-title: The global economic burden of dengue: A systematic analysis publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(16)00146-8 – volume: 16 start-page: 712 year: 2016 ident: 10.1016/j.crpvbd.2022.100107_bib26 article-title: The global burden of dengue: An analysis from the Global Burden of Disease Study 2013 publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(16)00026-8 – volume: 14 year: 2018 ident: 10.1016/j.crpvbd.2022.100107_bib30 article-title: Contributions from the silent majority dominate dengue virus transmission publication-title: PLoS Pathog. doi: 10.1371/journal.ppat.1006965 – volume: 91 start-page: 1079 year: 2014 ident: 10.1016/j.crpvbd.2022.100107_bib27 article-title: Impact of a spatial repellent on malaria incidence in two villages in Sumba, Indonesia publication-title: Am. J. Trop. Med. Hyg. doi: 10.4269/ajtmh.13-0735 – volume: 11 start-page: 365 year: 2018 ident: 10.1016/j.crpvbd.2022.100107_bib29 article-title: Model-based analysis of experimental data from interconnected, row-configured huts elucidates multifaceted effects of a volatile chemical on Aedes aegypti mosquitoes publication-title: Parasites Vectors doi: 10.1186/s13071-018-2919-0 – volume: 23 start-page: 260 year: 2022 ident: 10.1016/j.crpvbd.2022.100107_bib19 article-title: Evaluation of the protective efficacy of a spatial repellent to reduce malaria incidence in children in western Kenya compared to placebo: study protocol for a cluster-randomized double-blinded control trial (the AEGIS program) publication-title: Trials doi: 10.1186/s13063-022-06196-x – volume: 16 year: 2019 ident: 10.1016/j.crpvbd.2022.100107_bib31 article-title: Community-level impacts of spatial repellents for control of diseases vectored by Aedes aegypti mosquitoes publication-title: PLoS Comput. Biol. – year: 2022 ident: 10.1016/j.crpvbd.2022.100107_bib4 – volume: 5 start-page: e68 year: 2008 ident: 10.1016/j.crpvbd.2022.100107_bib15 article-title: Defining the challenges and proposing new solutions for Aedes aegypti-borne disease prevention publication-title: PLoS Med. doi: 10.1371/journal.pmed.0050068 – volume: 10 start-page: 545 year: 2010 ident: 10.1016/j.crpvbd.2022.100107_bib21 article-title: Changes in the burden of malaria in sub-Saharan Africa publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(10)70096-7 – volume: 11 start-page: 164 year: 2012 ident: 10.1016/j.crpvbd.2022.100107_bib1 article-title: Spatial repellents: from discovery and development to evidence-based validation publication-title: Malar. J. doi: 10.1186/1475-2875-11-164 – volume: 103 start-page: 344 year: 2020 ident: 10.1016/j.crpvbd.2022.100107_bib28 article-title: Efficacy of a spatial repellent for control of malaria in Indonesia: A cluster-randomized controlled trial publication-title: Am. J. Trop. Med. Hyg. doi: 10.4269/ajtmh.19-0554 – volume: 10 start-page: 337 year: 2011 ident: 10.1016/j.crpvbd.2022.100107_bib35 article-title: Costs and cost-effectiveness of malaria control interventions - a systematic review publication-title: Malar. J. doi: 10.1186/1475-2875-10-337 |
| SSID | ssj0002513374 |
| Score | 2.3631938 |
| Snippet | Spatial repellent (SR) products are envisioned to complement existing vector control methods through the continual release of volatile active ingredients (AI)... |
| SourceID | doaj pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 100107 |
| SubjectTerms | Clinical trials Cost-effectiveness Dengue from the special issue on Spatial Repellents in the Lab and Field to Protect Civilian and Military Public Health, Edited by Seth C. Britch, Kenneth Linthicum and Dan Kline Malaria Social science Spatial repellents WHO |
| Title | Spatial repellents: The current roadmap to global recommendation of spatial repellents for public health use |
| URI | https://dx.doi.org/10.1016/j.crpvbd.2022.100107 https://www.ncbi.nlm.nih.gov/pubmed/36590345 https://www.proquest.com/docview/2760168628 https://pubmed.ncbi.nlm.nih.gov/PMC9801085 https://doaj.org/article/63f523f78e99429a877efdf44797dd01 |
| Volume | 3 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV07b9swECaKTFmKBEkbJ03AAF2FyqLER7e2iGFkyBQD3giKR6IubMnwI7-_R1Iy7HjwklWiSJF35H1HHr8j5LtR6HMZnGmQD21WQmUzKUFlHq2p98xxaWKU7wsfT8rnaTXdS_UVYsISPXAauB-cefSVvJBOKVw7jRTCefBlKZQASDe30ObtOVNhDS5C2pJIwYwGSGQI-qf9vbkY3GVXy7c6EIUWRWQhCtlk9-xSpO8_ME_H8PN9FOWeWRpdkM8dnqS_Uj8uySfXXJF5SDSMikVXLhyuhFiJnxQVgtrExkRXrYGFWdJNSxMjCA2O8WLhuhRLtPV0fVQHRYBLEy82Tfcn6Xbtrslk9PT6Z5x1aRUyWxVqk0EhORS5VdLVQoIzvshxjAXnvjaeq9oIhFWCeWUrlKMYgh1aBSU6jwAVA_aFnDVt424IlcwxZxBDlYgEpPDGK-DgEDTktWeqHBDWD6q2Hed4SH0x131w2T-dRKGDKHQSxYBku6-WiXPjRPnfQV67soExOz5APdKdHulTejQgope27sBHAhVY1exE84-9cmicm-HAxTSu3a51EQKOwhUcOSBfk7LsfpLxSuWsrLDdAzU66MXhm2b2N_J_K0QViJRvP6Lbd-Qcu8LSptI3crZZbd09wqxN_RBn1EPc__oPdrgm_w |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Spatial+repellents%3A+The+current+roadmap+to+global+recommendation+of+spatial+repellents+for+public+health+use&rft.jtitle=Current+research+in+parasitology+%26+vector-borne+diseases&rft.au=Achee%2C+Nicole+L.&rft.au=Perkins%2C+T.+Alex&rft.au=Moore%2C+Sean+M.&rft.au=Liu%2C+Fang&rft.date=2023-01-01&rft.pub=Elsevier&rft.eissn=2667-114X&rft.volume=3&rft_id=info:doi/10.1016%2Fj.crpvbd.2022.100107&rft.externalDocID=PMC9801085 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2667-114X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2667-114X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2667-114X&client=summon |